A clinician’s guide for navigating the world of attention deficit hyperactivity disorder medications
Gregory W. Mattingly(Washington University in St. Louis), Joel Young(Wayne State University)
Cited by 6
Related Papers
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
|CNS Spectrums|2009|93
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder
|Journal of the American Academy of Child & Adolescent Psychiatry|2015|63
Once-Daily Treatment With Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder
|Clinical Neuropharmacology|2011|61